Navigation Links
Exagen Diagnostics Enters Into Exclusive Agreement With EndoChoice
Date:2/16/2010

ALBUQUERQUE, N.M., Feb. 16 /PRNewswire/ -- Exagen Diagnostics, Inc., a molecular diagnostics laboratory that discovers, develops and markets proprietary genomic tests, today announced an exclusive sales and marketing agreement with EndoChoice, Inc. to promote its diagnostic services to gastroenterologists throughout the United States.

Under the agreement, EndoChoice's experienced, gastroenterology-focused sales force will introduce Exagen's proprietary gene expression tests for the diagnosis of Inflammatory Bowel Disease (IBD) and Irritable Bowel Syndrome (IBS).  Exagen developed these molecular tests through its discovery engine, Coperna®, which identified "gene activity signatures" associated with IBD and IBS.

Scott Glenn, Exagen's CEO said, "We are excited about the opportunity of partnering with EndoChoice to accelerate the adoption of our technology by gastroenterologists.  Our eXaIBD™ and eXaIBS™ tests have both high sensitivity and accuracy, helping to identify IBD and IBS from other diseases, avoiding an extensive series of exclusionary testing."

"EndoChoice is focused on satisfying the unmet needs of GI professionals by delivering innovative, best-in-class products and services," said Mark Gilreath, EndoChoice's CEO.  "We are pleased to offer Exagen's proprietary eXaIBD™ and eXaIBS™ tests because they provide a superior diagnostic tool to assist gastroenterologists and improve patient care."

About Exagen Diagnostics, Inc.

Exagen Diagnostics is the emerging leader in laboratory-discovered and developed genomic tests specifically designed to provide objective information to physicians and patients for more accurate, efficient diagnosis and better disease management. Using Coperna®, the company's proprietary, algorithm-driven computational tool and search engine that runs on high-performance computational clusters, it combines the ability to process massive amounts of data contained in genomic datasets with intelligent, rapid search methods. Coperna's targeted and precise discovery model has no conventional equivalent in the molecular diagnostics industry as it can identify relevant marker sets with superior sensitivity and specificity relative to markers identified via traditional analytical methods. For more information, please visit www.exagen.com.

About EndoChoice, Inc.

EndoChoice delivers innovative solutions to professionals in gastrointestinal endoscopy with its diverse portfolio of high-quality diagnostics, equipment, devices, supplies and services.   The company strives to cleverly exceed its customers' expectations through its nationwide sales force, exemplary customer care, superior products and easy online ordering.  For more information, visit www.endochoice.com.

SOURCE Exagen Diagnostics, Inc.

RELATED LINKS
http://www.exagen.com
http://www.endochoice.com

'/>"/>

SOURCE Exagen Diagnostics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Scott Glenn Joins Exagen Diagnostics as Chairman and CEO
2. AstraZeneca and Dako Sign Agreement to Develop Companion Diagnostics for Cancer Treatments
3. Sword Diagnostics Announces Availability of Proprietary Detection Technology for Ultrasensitive Immunoassays.
4. Inverness Medical Innovations Offers to Acquire Standard Diagnostics
5. Frost & Sullivan Recognizes IntelligentMDx for Its Commitment to the Advancement of Healthcare and Diagnostics
6. Fujirebio Diagnostics Named Life Sciences Company of the Year
7. U.S. Patent Office Issues Sword Diagnostics Patent for Highly Sensitive Immunodetection Technology
8. Arrayit Diagnostics Announces Sponsored Research Agreement With Wayne State University and Arrayit Corporation
9. Roche Diagnostics Opens State-of-the-Art Training Center in California
10. Quest Diagnostics Reveals New Genetic Discoveries for Testing for Leukemia, Lymphoma and Blood Clotting at 51st ASH Meeting and Exposition
11. Reportlinker Adds Molecular Diagnostics - A World Market Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2017)... Sept. 22, 2017 Janssen Biotech, Inc. (Janssen) ... letter from the U.S. Food and Drug Administration (FDA) ... sirukumab for the treatment of moderately to severely active ... clinical data are needed to further evaluate the safety ... active RA. ...
(Date:9/19/2017)... Sept. 19, 2017   ZirMed Inc ., a recognized ... announced that it has been ranked #1 by its users ... Rankings 2017 User Survey. ZirMed was recognized as the ... hospitals and medical centers over 200 beds and holds one ... technology user survey history. ...
(Date:9/12/2017)... and NEW YORK , Sept. 12, 2017   ... for global supply chains, has published the first annual edition of its ... of more than 20,400 companies evaluated by EcoVadis, based on Scorecard Ratings ... 2016. ... CSR Risk & Performance Index ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... ... “The Journey: From the Mountains to the Mission Field”: the story of a ... “The Journey: From the Mountains to the Mission Field” is the creation of published ... all ages and currently teaches a class of ladies at her church, which she ...
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare Compliance (FHC), ... will showcase a range of technology and learning solutions at the 68th Annual ... Expo to be held October 14–18, 2017 at the Mandalay Bay Resort in ...
(Date:10/12/2017)... New Orleans, LA (PRWEB) , ... October 12, 2017 , ... ... fitness centers in the U.S., announced today its plans to open a flagship location ... club will occupy the former Rooms To Go store next to Office Depot in ...
(Date:10/12/2017)... PALM CITY, Fla. (PRWEB) , ... October 12, 2017 , ... ... of cold therapy products, announced today the introduction of an innovative new design of ... the multipurpose pad so you get maximum comfort while controlling your pain while using ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, a ... health care, have expanded their existing home health joint venture through an agreement, ... been operating a joint venture home health company with Asante, delivering clinically integrated ...
Breaking Medicine News(10 mins):